CGEN CGEN
Company Profile ↓Company Overview
CGEN (CGEN) is a publicly traded company listed on with a market capitalization of $215.58M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 34.4%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 23.4%.
Revenue has grown at a 113.3% CAGR over the past five years.
Trades at an undemanding P/E of 6.0.
Maintains a net profit margin of 48.6%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $72.76M (+161.1% YoY); net profit $35.34M.
- Trailing 12 Months Year-on-year growth — revenue +161.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 113.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 113.28% |
| 1 Year: | 161.14% |
Stock Price Performance
| 1 Year: | +56.16% |
| 6 Months: | +25.27% |
| 3 Months: | -16.18% |
| 1 Month: | -4.60% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)47.37 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 34.4%.
- Healthy ROCE of 23.4%.
- Excellent profit margin of 48.6%.
- Compounding revenue at 113.3% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 26.4% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 2.28M | 1.26M | 1.89M | 67.33M | 2.18M |
| Cost of Revenue | - | 2.40M | 1.67M | 1.65M | 3.54M | 1.82M |
| Gross Profit | - | -116.00K | -408.00K | 241.00K | 63.80M | 352.00K |
| Operating Expenses | - | 8.28M | 8.02M | 8.13M | 7.75M | 9.37M |
| Operating Income | - | -8.39M | -8.43M | -7.89M | 56.04M | -9.02M |
| EBITDA | - | -8.39M | -8.43M | -7.89M | 56.04M | -9.02M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | -7.15M | -7.36M | -6.94M | 56.84M | -7.66M |
| Tax Provision | - | 31.00K | -17.00K | 40.00K | 0 | 5.00K |
| Net Income | - | -7.18M | -7.34M | -6.98M | 56.84M | -7.67M |
| Diluted EPS | - | -0.08 | -0.08 | -0.07 | 0.60 | -0.08 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 7.50M | 33.46M | 27.86M | 72.76M |
| Cost of Revenue | - | 975.00K | 2.00M | 7.93M | 9.25M |
| Gross Profit | - | 6.53M | 31.45M | 19.93M | 63.51M |
| Operating Expenses | - | 41.90M | 44.45M | 34.83M | 32.19M |
| Operating Income | - | -35.37M | -12.99M | -14.89M | 31.33M |
| EBITDA | - | -34.89M | -12.52M | -14.40M | 31.80M |
| Interest Expense | 25.00K | 27.00K | - | - | - |
| Pretax Income | - | -33.64M | -9.78M | -9.71M | 35.40M |
| Tax Provision | - | 58.00K | 8.97M | 4.52M | 54.00K |
| Net Income | - | -33.69M | -18.75M | -14.23M | 35.34M |
| Diluted EPS | - | -0.39 | -0.21 | -0.16 | 0.38 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 94.18M | 121.33M | 115.00M | 156.57M |
| Current Assets | - | 86.12M | 114.58M | 106.00M | 148.02M |
| Cash & Equivalents | - | 11.06M | 13.89M | 18.23M | 90.60M |
| Inventory | - | - | - | - | - |
| Receivables | 0 | 0 | 61.00M | 0 | - |
| Total Liabilities | - | 16.50M | 55.77M | 60.08M | 53.84M |
| Current Liabilities | - | 11.92M | 26.27M | 20.16M | 22.57M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 1.93M | 1.35M | 2.91M | 2.96M |
| Total Equity | - | 77.68M | 65.56M | 54.91M | 102.73M |
| Shares Outstanding | - | 86.62M | 89.24M | 89.54M | 94.55M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -34.11M | -35.89M | 49.60M | 31.63M |
| Investing Cash Flow | - | 37.06M | 35.51M | -46.25M | 30.00M |
| Financing Cash Flow | - | 353.00K | 3.08M | 554.00K | 10.60M |
| Capital Expenditure | - | -487.00K | -172.00K | -118.00K | -306.00K |
| Free Cash Flow | - | -34.60M | -36.06M | 49.49M | 31.33M |
| Net Change in Cash | - | 3.30M | 2.71M | 3.91M | 72.23M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 87.0% | 94.0% | 71.5% | 87.3% |
| Operating Margin % | - | -471.7% | -38.8% | -53.4% | 43.1% |
| Net Margin % | - | -449.3% | -56.1% | -51.1% | 48.6% |
| ROE % | - | -43.4% | -28.6% | -25.9% | 34.4% |
| ROCE % | - | -43.0% | -13.7% | -15.7% | 23.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CGEN
Compugen (CGEN) Stock Holds Steady As Cash Runway Extends To 2029 - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxNZ0d2QUlWYW0ycHpRQ3pXV3hSdGkwMGZZLW5pdnE4RExVcklTXzYtc3dCVm1YQ2F3VTE0SU10ejk5eWp2QnZrdzhxT1VxX3AwRGV0Zkk4cGRXbzlDNkhsc1NudTBlTy1sdk5LNXZ0ajNYTUYzaHRkZmJZdTN4NXRrRE9xSTJaWmN0RENURV…
COMPUGEN ($CGEN) Releases Q2 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxOdUtYVVNaaVJkek9wNUVfOGR1by1BWFNjcFBVOGk2d3p6QmFiWWRFc0ZteTQ2U2ZpNkJDdWNybHdLeEgtMXFUbXFvWlFCY2h0MXFTUmVRMVItUXQwYVpHendlR0xCZXRNaUVsQ0ZtSU9PV0t6NDgyS0V0N3lLZWxqODlCcTRxVmJT?oc=5"…
Compugen (CGEN) Stock Faces Mixed Analyst Target Changes After Cautious Valuation Revisions - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxOX1RVa0RQbFFTQjVxeTgwR1hTaWNMV1c1d1BLYnhQSE5pMlNJSzF2MkplbFRLejhzUVRUSkxIZkR6MGdPXy15enpTbW9qclZHZEtFWWlSbFV5NEV0dWxreW5qLU9JdXU0S2dfajhZY1lENDJndWRuNDkycGtNZnRDZmV0N2tOV3UzcWxDM2…
CGEN Looks 54.6% Undervalued on GF Value™ - GuruFocus
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxOdDZzd2NQeHZyaGJfN0pkY2EtNm5uaW5iZzBBYmxNWGRqZEdQNEhDN1BCWXhYTU1qM2cwSkxoQkFoX0NyMnk2MDA3Sk1EdkYzTEFlWjFDc0NXeXJmSDUwWHRtdE5PdVFlNkg0U190V1VZTW5nVVRLTkowQ0FBVmpJRUY5dnFUbDVQV0J5Vk…
Compugen (CGEN) grants CFO 26,000 options and 19,500 RSUs - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxON0pmVVhHZGVpU2xqLTdPTENScXgwLWJONDVNYi16a3ZQVEJtRXFKMEFWNk93WHBZUVl3a1daQ1k0U243Z2w5QktNS2M0dmpnSXdEXy15YWpydnhuNVhtdS1SWUNLUmN1dGhTTHI1UW5ZZDNDa1lPVUFBVkdvQjRvdWlYazlLLXJzRm9oLU…
CGEN Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1hQlpzLWZscWZ2ZlZwUlZKUERrV093SXBKSFF2eF9IaTVQRDQ3dEY1WnpqaHRsRU9mYTVrUURMMThFN1NSNE5GSDlVYkRvQXBhcmM3UEhoVFVwVThNcTQ4OW5pMEpPanlQa0pQQ0Mwd0lHMG9ITDNGSnp3?oc=5" target="_blank">CGE…
CGEN — Frequently Asked Questions
What is the current share price of CGEN?
As of 2026-08-05 17:25 PDT, CGEN trades at $2.28 on NASDAQ/NYSE. Its 52-week range is $1.33 to $3.10.
What is the market capitalisation of CGEN?
CGEN has a market capitalisation of $215.58M on NASDAQ/NYSE.
What is the P/E ratio of CGEN?
CGEN trades at a trailing price-to-earnings (P/E) ratio of 6.00. Its price-to-book (P/B) ratio is 2.10.
What is the return on equity (ROE) of CGEN?
CGEN has a return on equity (ROE) of 34.40%. Its return on capital employed (ROCE) is 23.38%.
Is CGEN a good stock to buy?
This page provides a data-driven analysis of CGEN, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.